ArticleVaccine2009
Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Article
- Differential effects of inosine monophosphate dehydrogenase (IMPDH/GuaB) inhibition inJournal of bacteriology · 2024Article
- Development, Strategies, and Challenges for Tularemia Vaccine.Current microbiology · 2024Review
- A journey into the regulatory secrets of theFrontiers in pharmacology · 2024Review
- The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection.Pathogens (Basel, Switzerland) · 2021Article
- A primitive type of renin-expressing lymphocyte protects the organism against infections.Scientific reports · 2021Article
- Characterization of Schu S4Virulence · 2020Article
- Deletion of the Major Facilitator Superfamily TransporterInfection and immunity · 2018Article
- Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.PloS one · 2018Article
- Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With VirulentFrontiers in cellular and infection microbiology · 2018Review
- Benzoxazoles, Phthalazinones, and Arylurea-Based Compounds with IMP Dehydrogenase-Independent Antibacterial Activity against Francisella tularensis.Antimicrobial agents and chemotherapy · 2017Article
- Tularemia vaccines.Folia microbiologica · 2016Review
- De Novo Guanine Biosynthesis but Not the Riboswitch-Regulated Purine Salvage Pathway Is Required for Staphylococcus aureus Infection In Vivo.Journal of bacteriology · 2016Article
- Gene replacement and quantitative mass spectrometry approaches validate guanosine monophosphate synthetase as essential forBiochemistry and biophysics reports · 2015Article
- Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates.Pathogens and disease · 2015Article
- Signature-tagged mutagenesis of Vibrio vulnificus.The Journal of veterinary medical science · 2015Article
- Mutational Analysis of the Chlamydia muridarum Plasticity Zone.Infection and immunity · 2015Article
- Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.Infection and immunity · 2014Article
- Article
- Inactivation of the Rgg2 transcriptional regulator ablates the virulence of Streptococcus pyogenes.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Francisella tularensis, the etiologic agent of tularemia, can cause severe and fatal infection after inhalation of as few as 10 -- 100CFU. F. tularensis is a potential bioterrorism agent and, therefore, a priority for countermeasure development. Vaccination with the live vaccine strain (LVS), developed from a Type B strain, confers partial protection against aerosal exposure to the more virulent Type A strains and provides proof of principle that a live attenuated vaccine strain may be efficacious. However LVS suffers from several notable drawbacks that have prevented its licensure and widespread use. To address the specific deficiencies that render LVS a sub-optimal tularemia vaccine, we engineered F. tularensis LVS strains with targeted deletions in the guaA or guaB genes that encode critical enzymes in the guanine nucleotide biosynthetic pathway. F. tularensis LVSDeltaguaA and LVSDeltaguaB mutants were guanine auxotrophs and were highly attenuated in a mouse model of infection. While the mutants failed to replicate in macrophages, a robust proinflammatory cytokine response, equivalent to that of the parental LVS, was elicited. Mice vaccinated with a single dose of the F. tularensis LVSDeltaguaA or LVSDeltaguaB mutant were fully protected against subsequent lethal challenge with the LVS parental strain. These findings suggest the specific deletion of these target genes could generate a safe and efficacious live attenuated vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.